Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK
11:07am, Friday, 14'th Oct 2022 Zacks Investment Research
Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.
Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing Both
04:37pm, Thursday, 13'th Oct 2022
Back in September 2021,Moderna's and Merck's market cap valuation were only a few billions apart at ~$175bn and ~$182bn, respectively. As the more diversified, future-proofed pharma, it makes sense th
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
03:27pm, Thursday, 13'th Oct 2022 Zacks Investment Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab
02:15pm, Thursday, 13'th Oct 2022 Zacks Investment Research
FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.
Moderna and Merck ink US$250mln deal to develop world's first cancer vaccine
03:42am, Thursday, 13'th Oct 2022
The group that developed a Covid jab using messenger RNA (mRNA) technology has inked a US$250mln deal with to create a cancer vaccine with one of the world's largest pharma companies. Moderna Theraput
These 2 Stocks Gave Investors a Nice Surprise Wednesday
11:16pm, Wednesday, 12'th Oct 2022 The Motley Fool
Markets moved slightly lower in advance of the latest data on inflation.
U.S. stocks end lower with S&P 500 booking 6-day losing streak as investors digest Fed minutes, await CPI
08:19pm, Wednesday, 12'th Oct 2022 MarketWatch
U.S. stock indexes ended a volatile session lower on Wednesday after hotter-than-expected producer price inflation data and minutes from the Federal Reserve's September meeting deepened concerns that
Moderna and Merck enter joint venture to develop cancer vaccine
06:40pm, Wednesday, 12'th Oct 2022
Yahoo Finance anchors Seana Smith and Dave Brigs discuss pharmaceutical manufacturers Moderna and Merck are partnering together to develop a cancer vaccine.
Moderna to develop a personalized cancer vaccine with Merck
04:21pm, Wednesday, 12'th Oct 2022
Michael Yee, Jefferies managing director, joins 'Closing Bell' to share details on the Moderna and Merck announcement about a personalized cancer treatment for people with melanoma and what it means f
Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine
03:47pm, Wednesday, 12'th Oct 2022
The move is welcomed by investors because if successful, it would help Moderna diversify its revenue and profits away from COVID-19 vaccines.
Why Moderna Stock Is Bolting Higher Today
03:24pm, Wednesday, 12'th Oct 2022 The Motley Fool
A cancer vaccine deal with pharma heavyweight Merck is lighting a fire underneath the biotech's shares today.
Here's Why Merck (MRK) is a Strong Value Stock
01:40pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
01:38pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.
What's going to break next? Look for leverage and artificial constraints, says this fund manager
01:16pm, Wednesday, 12'th Oct 2022 MarketWatch
One fund sees a rough fourth quarter both for U.S. stocks and commodities, anticipating consumer spending will finally turn and earnings growth expectations to ratchet down.
Moderna, Merck to jointly develop cancer vaccine
12:21pm, Wednesday, 12'th Oct 2022
Yahoo Finance Live's Julie Hyman discusses the rise in shares for Merck and Moderna after Moderna announced the joint development and potential sale of an mRNA-based cancer vaccine.
